Abstract
Background: Sarcopenia has been associated with poor outcomes in patients with cirrhosis and solid tumours. Objective: Analyse the influence of sarcopenia on survival and treatment duration in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. Methods: We conducted a multicentre, retrospective study on 96 patients with advanced HCC treated with sorafenib, all with available abdominal computed tomography (CT) scan within 30 days from treatment start. Anthropometric, laboratory, treatment and follow-up data were collected. Sarcopenia was defined by reduced skeletal muscle index calculated from an L3 section CT image. Results: Sarcopenia was present in 49% of patients. Patients were divided into two groups according to sarcopenia: age was significantly higher in the sarcopenic group (SG) (66 years (31–87) versus 72 years (30–84), p = 0.04], with no difference in other baseline characteristics. The SG showed shorter overall survival (OS) (39 (95% confidence interval (CI) 26–50) versus 61 (95% CI 47–77) weeks (p = 0,01)) and shorter time on treatment (12.3 (95% CI 8–19) versus 25.9 (95% CI 15–33) weeks (p = 0.0044)). At multivariate analysis, sarcopenia was independently associated to reduced OS (p = 0.03) and reduced time on treatment (p = 0.001). Conclusion: Sarcopenia is present in almost half of patients with advanced HCC, and is associated with reduced survival and reduced duration of oral chemotherapy.
| Original language | English |
|---|---|
| Pages (from-to) | 1039-1048 |
| Journal | United European Gastroenterology Journal |
| Volume | 6 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - 2018 |
Fingerprint
Keywords
- CT scan
- HCC
- performance status
- prognostic factor
- skeletal muscle index
ASJC Scopus subject areas
- Oncology
- Gastroenterology
Cite this
Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment. / Antonelli, Giulio; Gigante, Elia; Iavarone, Massimo; Begini, Paola; Sangiovanni, Angelo; Iannicelli, Elsa; Biondetti, Piero; Pellicelli, Adriano M.; Miglioresi, Lucia; Marchetti, Paolo; Lampertico, Pietro; Marignani, Massimo.
In: United European Gastroenterology Journal, Vol. 6, No. 7, 2018, p. 1039-1048.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment
AU - Antonelli, Giulio
AU - Gigante, Elia
AU - Iavarone, Massimo
AU - Begini, Paola
AU - Sangiovanni, Angelo
AU - Iannicelli, Elsa
AU - Biondetti, Piero
AU - Pellicelli, Adriano M.
AU - Miglioresi, Lucia
AU - Marchetti, Paolo
AU - Lampertico, Pietro
AU - Marignani, Massimo
PY - 2018
Y1 - 2018
N2 - Background: Sarcopenia has been associated with poor outcomes in patients with cirrhosis and solid tumours. Objective: Analyse the influence of sarcopenia on survival and treatment duration in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. Methods: We conducted a multicentre, retrospective study on 96 patients with advanced HCC treated with sorafenib, all with available abdominal computed tomography (CT) scan within 30 days from treatment start. Anthropometric, laboratory, treatment and follow-up data were collected. Sarcopenia was defined by reduced skeletal muscle index calculated from an L3 section CT image. Results: Sarcopenia was present in 49% of patients. Patients were divided into two groups according to sarcopenia: age was significantly higher in the sarcopenic group (SG) (66 years (31–87) versus 72 years (30–84), p = 0.04], with no difference in other baseline characteristics. The SG showed shorter overall survival (OS) (39 (95% confidence interval (CI) 26–50) versus 61 (95% CI 47–77) weeks (p = 0,01)) and shorter time on treatment (12.3 (95% CI 8–19) versus 25.9 (95% CI 15–33) weeks (p = 0.0044)). At multivariate analysis, sarcopenia was independently associated to reduced OS (p = 0.03) and reduced time on treatment (p = 0.001). Conclusion: Sarcopenia is present in almost half of patients with advanced HCC, and is associated with reduced survival and reduced duration of oral chemotherapy.
AB - Background: Sarcopenia has been associated with poor outcomes in patients with cirrhosis and solid tumours. Objective: Analyse the influence of sarcopenia on survival and treatment duration in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. Methods: We conducted a multicentre, retrospective study on 96 patients with advanced HCC treated with sorafenib, all with available abdominal computed tomography (CT) scan within 30 days from treatment start. Anthropometric, laboratory, treatment and follow-up data were collected. Sarcopenia was defined by reduced skeletal muscle index calculated from an L3 section CT image. Results: Sarcopenia was present in 49% of patients. Patients were divided into two groups according to sarcopenia: age was significantly higher in the sarcopenic group (SG) (66 years (31–87) versus 72 years (30–84), p = 0.04], with no difference in other baseline characteristics. The SG showed shorter overall survival (OS) (39 (95% confidence interval (CI) 26–50) versus 61 (95% CI 47–77) weeks (p = 0,01)) and shorter time on treatment (12.3 (95% CI 8–19) versus 25.9 (95% CI 15–33) weeks (p = 0.0044)). At multivariate analysis, sarcopenia was independently associated to reduced OS (p = 0.03) and reduced time on treatment (p = 0.001). Conclusion: Sarcopenia is present in almost half of patients with advanced HCC, and is associated with reduced survival and reduced duration of oral chemotherapy.
KW - CT scan
KW - HCC
KW - performance status
KW - prognostic factor
KW - skeletal muscle index
UR - http://www.scopus.com/inward/record.url?scp=85047943609&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047943609&partnerID=8YFLogxK
U2 - 10.1177/2050640618781188
DO - 10.1177/2050640618781188
M3 - Article
AN - SCOPUS:85047943609
VL - 6
SP - 1039
EP - 1048
JO - United European Gastroenterology Journal
JF - United European Gastroenterology Journal
SN - 2050-6406
IS - 7
ER -